CARGO Therapeutics Inc (NASDAQ:CRGX) does about 765.24K shares in volume on a normal day but saw 1373212 shares change hands in the recent trading day. The company now has a market cap of 219.04M USD. Its current market price is $4.75, marking an increase of 4.17% compared to the previous close of $4.56. The 52 week high reached by this stock is $25.45 whilst the lowest price level in 52 weeks is $3.00. The script in recent trading has seen the stock touch a high of $7 and a low of $7.
2 analysts observing the CARGO Therapeutics Inc (CRGX) stock have set the 12-month price targets for the company’s shares at between $7 and $7. The consensus objective for the share price is $3.23, suggesting that the stock has a potential downside of -47.06% over the period. The median price target is 32.14% away from the current levels at $7.
FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Hold the stock.
Truist also downgraded the stock to “Hold” from Buy on January 30, 2025 at a price target of $32-$7. Piper Sandler downgraded its price target at $34-$4.
The current price level is 13.30%, 11.50%, and -59.35% away from its SMA20, SMA50, and SMA200 respectively, with the CRGX price moving below the 50-day SMA on current market day. CARGO Therapeutics Inc (CRGX) stock is up 11.76% over the week and 17.28% over the past month. Its price is -67.06% year-to-date and -75.22% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.48 and -1.96 for whole year.
Its 12-month price target is $7. To reach the target analysts have set, the stock logically needs to shrink -47.06 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $7, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $7.
Outstanding shares total 46.05M with insiders holding 0.66% of the shares and institutional holders owning 104.82% of the company’s common stock. The company has a return on investment of -69.65% and return on equity of -65.94%. The beta has a value of 0.29. Price to book ratio is 0.77.
